TabletsClinical Overview
Lapatinib Tablets (250mg) is an oral dual tyrosine kinase inhibitor of both EGFR (ErbB1) and HER2/neu (ErbB2) on the PMBI formulary. It reversibly binds to the intracellular ATP-binding domain of both receptors, inhibiting receptor phosphorylation and shutting down downstream MAPK and PI3K/Akt survival cascades in HER2-overexpressing tumor cells. Able to cross the blood-brain barrier. Indicated in combination with capecitabine for advanced or metastatic HER2-positive breast cancer progressing after prior trastuzumab, anthracyclines, and taxanes, and with letrozole for hormone receptor-positive/HER2-positive breast cancer.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally 1250 mg (five 250 mg tablets) once daily continuously on an EMPTY STOMACH: at least 1 hour before or 1 hour after a meal with a full glass of water. Swallow tablets whole. Do not divide doses.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Diarrhea (frequent, onset typically within 6 days), acneiform rash, nausea, hand-foot syndrome (with capecitabine), fatigue, stomatitis. Rare/Severe: Decreased left ventricular ejection fraction (LVEF / cardiomyopathy), severe hepatotoxicity, severe interstitial lung disease, and QT prolongation.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Black Box Warning: Severe hepatotoxicity; monitor liver transaminases every 4 to 6 weeks. Perform baseline and periodic echocardiography (LVEF evaluation). Must be taken on an empty stomach. Proactively manage diarrhea with loperamide at the first loose stool. Avoid grapefruit juice.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, oncological diagnosis, or chemotherapy protocol guidance. Cancer therapies require specialized administration under the direct supervision of a registered medical oncologist in an accredited healthcare facility.